Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „moderate“
Suchtreffer
Begriffe & Kennungen
Bemfola · 4.8 · Mild or moderate ovarian hyperstimulation syndrome (OHSS) has been commonly reported and should be considered
Eintrag öffnenBemfola · 4.8 · Reproductive system and breast disorders Very common: Ovarian cysts Common: Mild or moderate OHSS (including a
Eintrag öffnenBimzelx · 4.8 · The majority of infections consisted of non-serious mild to moderate upper respiratory tract infections such a
Eintrag öffnenBosulif · 4.5 · If a strong or moderate CYP3A inhibitor must be administered during bosutinib treatment, an interruption of bo
Eintrag öffnenBosulif · 4.5 · In a study of 20 healthy subjects, in whom a single dose of 125 mg aprepitant (a moderate CYP3A inhibitor) was
Eintrag öffnenBraftovi · 4.5 · CYP3A4 inhibitors Co-administration of moderate (diltiazem) and strong (posaconazole) CYP3A4 inhibitors with s
Eintrag öffnenBrinavess · 4.5 · Vernakalant is a moderate, competitive inhibitor of CYP2D6. However, acute intravenous administration of verna
Eintrag öffnenBrintellix · 4.8 · Nausea Nausea was usually mild or moderate and occurred within the first two weeks of treatment. The reactions
Eintrag öffnenBrintellix · 4.8 · Nausea Nausea was usually mild or moderate and occurred within the first two weeks of treatment. The reactions
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · 27 Carbamazepine Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increase
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Carbamazepine Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increased c
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · Carbamazepine Brivaracetam is a moderate reversible inhibitor of epoxide hydrolase resulting in an increased c
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of BRUKINSA and medicinal products that strongly or moderately inhibit CYP3A can increase zanu
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of BRUKINSA and medicinal products that strongly or moderately inhibit CYP3A can increase zanu
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of zanubrutinib and strong or moderate inducers of CYP3A can decrease zanubrutinib plasma conc
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of zanubrutinib and strong or moderate inducers of CYP3A can decrease zanubrutinib plasma conc
Eintrag öffnenBrukinsa · 4.5 · If a moderate CYP3A inhibitor must be used (e.g., erythromycin, ciprofloxacin, diltiazem, dronedarone, flucona
Eintrag öffnenBrukinsa · 4.5 · If a moderate CYP3A inhibitor must be used (e.g., erythromycin, ciprofloxacin, diltiazem, dronedarone, flucona
Eintrag öffnenBrukinsa · 4.5 · Moderate CYP3A inhibitors
Eintrag öffnenBrukinsa · 4.5 · Moderate CYP3A inhibitors
Eintrag öffnen